- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01403233
Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects (StevReb-PK)
An Open-label, Sequential Supplementation Study Comparing the Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects
The purpose of the study is to examine the bioavailability of cogniVida™ in 10 healthy male subjects after consumption of two different doses of cogniVida™ (50 mg and 100 mg) and to compare the plasma values with values obtained in subjects receiving rebaudioside A (303.68 mg). In addition, also safety and tolerability parameters 24 hours after ingestion of the study compounds will be determined.
cogniVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The investigators do not claim that this supplement is meant to treat any ailment.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Ontario
-
London, Ontario, Kanada, N6A 5R8
- KGK Synergize Inc
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Sex: Male, age 30 - 50 years
- Subject is willing to maintain his or her habitual diet and physical activity patterns throughout the study period.
- Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results
- Subject has a body mass index (BMI) of ≥20.00 and <28.00 kg/m2 at screening.
- Subject is willing to refrain from consuming drinks containing grapefruit 7 days prior to test days.
- Subject is willing to refrain from consuming caffeine, caffeine-containing products and alcoholic drinks 24 h prior to test days and until the end of each assessment period.
- Subject is willing to refrain from vigorous physical activity 12 h prior to test days.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria:
- Subject has a positive drug screening of amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, 3,4-methylenedioxymethamphetamine, opiates or tricyclic antidepressants at screening.
- Subjects has a positive blood alcohol and breath carbon monoxide test at screening.
- Subject has abnormal laboratory test results of clinical significance, including, but not limited to: Epidermal-Growth-Factor-Receptor (eGFR) <60mL/min/1.73m2, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5X the upper limit of normal at screening.
- Subject has donated more than 300 mL of blood or has lost a significant amount of blood during the three months prior to screening.
- Anemia of any etiology defined as hemoglobin < 140g/L for males and < 123g/L for female
- Subject has uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the average blood pressure measured at screening.
- Subject has a history or presence of cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorders.
- Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Subject has a history or presence of cancer in the prior five years, except for non-melanoma skin cancer.
- Excessive habitual caffeine consumption (>300 mg caffeine/d or ≥ 3 cups of caffeinated coffee/d), following screening and throughout the study period.
- Use of antibiotics or signs of active systemic infection. Treatment visits will be rescheduled to allow the subject to wash off of the antibiotic for at least one month prior to any test visit.
- Use of dietary supplements containing any of the following: ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 ug/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)or a combination of EPA + DHA (≥500 mg/d) within 2 weeks prior to screening.
- Consumption of stevia extract (reb A / steviosides) sweetened products/drinks or stevia leaves within one month of the study.
- Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit.
- Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- Subject has a known allergy or sensitivity to study product or any ingredients of the study product or meals provided.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Crossover Assignment
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: cogniVida™ 50 mg/day
|
2 capsules 25 mg (total 50 mg) cogniVida™ once a day
|
Experimentální: cogniVida™ 100 mg/den
|
4 capsules 25 mg (total 100 mg) cogniVida™ once a day
|
Aktivní komparátor: Rebaudioside-A 303.7 mg/day
|
4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Plasma Area under the Curve (AUC) (0-72 hours) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Časové okno: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Time to plasma peak (Tmax) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Časové okno: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Plasma Peak Concentration (Cmax) being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Časové okno: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Time to reach half of peak concentration in plasma T1/2 being produced after cogniVida™ (50 and 100 mg) and rebaudioside A (303.68 mg) consumption
Časové okno: 0 - 72 hours
|
Blood sampling timepoints: cogniVida: 0 min, 15min, 30min, 45min, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48, and 72h after dosing. RebA: 0 min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36, 48, and 72h after dosing |
0 - 72 hours
|
Vital signs
Časové okno: 24 hours after each supplementation
|
Vital signs as safety parameters being measured 24 h after each supplementation.
|
24 hours after each supplementation
|
White blood cell (WBC) count (Routine Haematology)
Časové okno: 24 hours after each supplementation
|
White blood cells will be counted as a routine haematology parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Hemoglobin (Routine Haematology)
Časové okno: 24 hours after each supplementation
|
Hemoglobin will be measured as a routine haematology parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Blood urea nitrogen (BUN) (Clinical Chemistry)
Časové okno: 24 hours after each supplementation
|
Blood urea nitrogen will be measured as a routine clinical chemistry parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Cystatin-C (Clinical Chemistry)
Časové okno: 24 hours after each supplementation
|
Cystatin-C will be measured as a routine clinical chemistry parameter to assess safety 24 h after each supplementation.
|
24 hours after each supplementation
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- 2010-06-01-STEV
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Zdravý
-
University of ZurichDokončenoOutcome Assessment, Health CareŠvýcarsko
-
University of BernUniversity Hospital Inselspital, BerneDokončenoNeuroscience of Dreaming, HealthŠvýcarsko
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... a další spolupracovníciAktivní, ne náborPreventivní zdravotní služby (PREV HEALTH SERV)Spojené státy
-
Queens College, The City University of New YorkNáborZveřejnění článků předložených American Journal of Public HealthSpojené státy
-
Kliniek ViaSanaSt. Anna Ziekenhuis, Geldrop, NetherlandsDokončenoBolest | Užívání opioidů | Totální náhrada kolena | Aplikace E-healthHolandsko
-
Istanbul University - Cerrahpasa (IUC)NáborKardiochirurgie, Srdeční chirurgie, Výuka propouštění, Ošetřovatelství, Telenutriční péče, m-Health, Kvalita života, ZotaveníKrocan
-
FIDMAG Germanes HospitalàriesUniversity of BarcelonaZatím nenabírámePorucha duševního zdraví | Duševní zdraví wellness 1 | Role sestry | Care Acceptor, Health | Vztah, sestra pacienta
-
University of AarhusRegion MidtJylland Denmark; Tryg Danmark; Randers Municipality, DenmarkNeznámýKardiovaskulární onemocnění | Podpora zdraví | Duševní zdraví | Fyzická nečinnost | Self-reported Quality of HealthDánsko
-
Yorkshire Ambulance Service NHS TrustUniversity of BradfordZatím nenabírámeTestování Point of Care | Klinické rozhodování | Komunitní urgentní a pohotovostní péče | Allied Health Professional
-
4Life Research, LLCDokončenoSin Health | Hydratace pleti | Kožní vrásky | Kožní porfyriny | Červené skvrny na kůži obličeje | Červená vaskulatura kůže obličejeSpojené státy
Klinické studie na cogniVida 50mg/day
-
Johnson & Johnson Vision Care, Inc.DokončenoKrátkozrakostSpojené státy
-
University of Maryland, BaltimoreDokončenoChronická onemocnění ledvin | Bezpečnostní problémySpojené státy
-
Johnson & Johnson Vision Care, Inc.DokončenoZraková ostrostSpojené státy
-
Karolinska InstitutetRegion Stockholm; ForteAktivní, ne nábor
-
University of HoustonDokončenoEpiteliopatie stíračů víčekSpojené státy
-
Unilever R&DWorld Dental Federation (FDI)DokončenoZubní plak | Chování | Chování, zdravíIndonésie, Nigérie
-
Johnson & Johnson Vision Care, Inc.DokončenoOční fyziologieSpojené státy
-
Massachusetts General HospitalAmerican Cancer Society, Inc.Ukončeno
-
University of Nevada, Las VegasNáborTBI (traumatické poranění mozku) | Cvičení | Otřes mozku | Rehabilitace | Chůze | Poznání | Klinická studie | Psychosociální fungování | mikroRNA | Mobilní aplikace | Sliny | Vize, OkulárSpojené státy
-
University of Wisconsin, MadisonUrban League of Greater Madison; African American Council of Churches Madison; Second Baptist Church a další spolupracovníciDokončenoDeprese | Samospráva | PovědomíSpojené státy